Kala Pharmaceuticals Inc (KALA) — Cash Flow-to-Debt Ratio
Kala Pharmaceuticals Inc (KALA) has a Cash Flow-to-Debt Ratio of -1.83x as of March 2026, meaning its operating cash flow of $-4.56 Million could theoretically repay -2% of its total liabilities ($2.49 Million) in one year. See KALA FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kala Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Kala Pharmaceuticals Inc across 13 annual periods. For the full cash flow conversion analysis, see Kala Pharmaceuticals Inc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Kala Pharmaceuticals Inc (2013–2025)
Year-by-year debt coverage analysis for Kala Pharmaceuticals Inc. Check how high is Kala Pharmaceuticals Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -12.83x | $-31.99 Million | $2.49 Million | ▼ -1783.8% |
| 2024 | -0.68x | $-29.38 Million | $43.15 Million | ▼ -18.1% |
| 2023 | -0.58x | $-27.93 Million | $48.45 Million | ▲ +50.4% |
| 2022 | -1.16x | $-78.91 Million | $67.85 Million | ▼ -31.8% |
| 2021 | -0.88x | $-108.23 Million | $122.62 Million | ▼ -18.4% |
| 2020 | -0.75x | $-90.69 Million | $121.61 Million | ▼ -0.2% |
| 2019 | -0.74x | $-92.72 Million | $124.63 Million | ▼ -59.4% |
| 2018 | -0.47x | $-54.12 Million | $115.98 Million | ▲ +63.8% |
| 2017 | -1.29x | $-34.10 Million | $26.45 Million | ▼ -532.0% |
| 2016 | -0.20x | $-27.35 Million | $134.09 Million | ▲ +80.8% |
| 2015 | -1.06x | $-15.09 Million | $14.24 Million | ▲ +41.6% |
| 2014 | -1.82x | $-15.36 Million | $8.46 Million | ▼ -15.1% |
| 2013 | -1.58x | $-10.84 Million | $6.87 Million | — |